PULMONARY EDEMA THERAPEUTICS MARKET ANALYSIS

Regional Analysis

Global Pulmonary Edema Therapeutics Market – Regional Insights

Among regions, North America is expected to account for the largest share in global pulmonary edema therapeutics market during the forecast period, owing to the recent approvals for the treatment of heart failure, a major cause for pulmonary edema. For instance, on May 08, 2020, Amgen Inc. and Cytokinetics Inc. who had collaborated, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as cardiac myotrope, is being developed for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF). Heart failure is a severe condition, which leads to cardiogenic pulmonary edema. Amgen Inc. is U.S.-based multinational biopharmaceutical company, which manufactures biologic therapies for serious illnesses like cancer and cardiovascular diseases. Cytokinetics is a late-stage biopharmaceutical company specializing in the discovery, development, and commercialization of first-in-class muscle activators.

Moreover, due to increasing collaborations and sales partnerships, Europe may witness a lucrative growth in global pulmonary edema therapeutics market over the forecast period. For instance, on November 19, 2020, Novartis International AG, one of the leading pharmaceutical company, announced an exclusive global license and collaboration agreement with Mesoblast to develop, commercialize, and manufacture remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19. Remestemcel-L is an investigational therapy that consists of culture-expanded mesenchymal stromal cells derived from an unrelated donor's bone marrow. Acute respiratory distress syndrome (ARDS) is one of the major non-heart related problems that leads to non-cardiogenic pulmonary edema. Mesoblast Ltd. is a company, which develops treatments for inflammatory ailments, cardiovascular disease, and back pain. These factors are expected to support global pulmonary edema therapeutics market growth over the forecast period.